SCHEMBL3346550

SCHEMBL3346550

NCCOC(c1cccc(Cl)c1)c1cccc(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.45
TDO2 P48775 4/20 0.45
AOC3 Q16853 1/20 0.38
TAAR1 Q96RJ0 2/20 0.37
SLC6A4 P31645 3/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A3 Q01959 2/20 0.36
OPRM1 P35372 2/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD1 P21728 1/20 0.35
TBXA2R P21731 1/20 0.35
DRD3 P35462 1/20 0.35
PNMT P11086 1/20 0.35
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
OPRL1 P41146 1/20 0.34
HTR2C P28335 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3641858 0.90 IDO1 (0.38) IDO1TDO2AOC3TAAR1SLC6A4
SCHEMBL13305060 0.78 IDO1 (0.41) IDO1TDO2AOC3SLC6A4SLC6A2
SCHEMBL3341361 0.78 IDO1 (0.41) IDO1TDO2AOC3SLC6A4SLC6A2
SCHEMBL3340697 0.76 HPGD (0.45) IDO1TDO2
SCHEMBL3641860 0.72 IDO1 (0.36) IDO1TDO2AOC3OPRM1OPRD1
SCHEMBL28548488 0.72 IDO1 (0.58) IDO1TDO2SLC6A4SLC6A2SLC6A3
SCHEMBL14607854 0.71 IDO1 (0.53) IDO1TDO2AOC3TAAR1
SCHEMBL3346119 0.71 ACP3 (0.42) IDO1TDO2SLC6A4SLC6A2SLC6A3
SCHEMBL7288351 0.69 SCN1A (0.57) TAAR1SLC6A4SLC6A2SLC6A3OPRM1
Bromomethane SCHEMBL5569429 0.69 SLC6A2 (0.56) SLC6A4SLC6A2SLC6A3OPRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
EP-2170815-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2010-04-07 EP disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160424-A1 RENIN INHIBITORS ACE, REN, DNPEP IDO1 3729/4885TDO2 4190/4885AOC3 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.